P. Santabárbara

8.5k citations
33 papers · 6.7k indexed · 3 hit papers · h-index 15
Topics
Lung Cancer Research Studies (11 papers)Lung Cancer Treatments and Mutations (11 papers)Lymphoma Diagnosis and Treatment (6 papers)
Partner nations
United StatesSpainCanada

In The Last Decade

P. Santabárbara

33 papers receiving 6.5k citations

Hit Papers

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer200220262010201820052004200210002.0k3.0k4.0k

Peers

P. Santabárbara
Comparison fields: 5 of 103
  • Oncology 4.5k
  • Pulmonary and Respiratory Medicine 4.5k
  • Molecular Biology 1.5k
  • Genetics 930
  • Pathology and Forensic Medicine 912
Replace Andrea Kay with:
Andrea Kay United States
David Lebwohl United States
Dimosthenis Skarlos Greece
Sang‐We Kim South Korea
Steven D. Averbuch United States
Ulrik Lassen Denmark
Lini Pandite United States
Michaela Lehle Switzerland
Jonathan Polikoff United States
Hossein Borghaei United States
P. Santabárbara relative to Andrea Kay United States Andrea Kay's profile →
Citations per field
00.5×1.7×
Andrea Kay · 1×
Citations per year

Countries citing papers authored by P. Santabárbara

Since Specialization
Citations

This map shows the geographic impact of P. Santabárbara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Santabárbara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Santabárbara more than expected).

Fields of papers citing papers by P. Santabárbara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Santabárbara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Santabárbara. The network helps show where P. Santabárbara may publish in the future.

Co-authorship network of co-authors of P. Santabárbara

This figure shows the co-authorship network connecting the top 25 collaborators of P. Santabárbara. A scholar is included among the top collaborators of P. Santabárbara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Santabárbara. P. Santabárbara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 18
2 47
3 4
4 12
5 7
6 27
7 3
8 140
9
Erlotinib in Previously Treated Non–Small-Cell Lung Cancerbreakdown →
4281
10 2
11 16
12
Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug.
28
13
A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
2
14 84
15 2
16 9
17 53
18 61
19 6
20 1

About P. Santabárbara

P. Santabárbara is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Reproductive Medicine, having authored 33 papers that have together received 6.7k indexed citations. Recurring topics across this work include Lung Cancer Research Studies (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Lymphoma Diagnosis and Treatment (6 papers). The work is most often cited by research in Oncology (4.5k citations), Pulmonary and Respiratory Medicine (4.5k citations) and Genetics (930 citations). P. Santabárbara has collaborated with scholars based in United States, Spain and Canada. Frequent co-authors include Gary M. Clark, Lesley Seymour, Frances A. Shepherd, Andrea Bezjak, Dongsheng Tu, Michael Smylie, Sumitra Thongprasert, Mircea Dediu, D. Johnston and Daniel de Castro. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026